abbott expans product portfolio underscor firm
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim oct
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
abbott expand medic devic footprint addit
st jude medic continu improv profit
segment nutrit devic diagnost establish
pharmaceut although abbott made progress
last five year still lag key rival profit measur
despit compet busi character
abbott effort improv effici includ streamlin
distribut channel build facil lower-cost locat
like china india demonstr success
still room improv look compani
consolid profit think abbott emphasi margin
improv pay next five year
like manag turn attent new sourc
growth view abbott new freestyl libr blood glucos
monitor offer compel innov anticip
addit veropharm provid abbott
substanti footprint latin america russia establish
pharmaceut product also applaud sale abbott epp
busi develop market optic unit reshuffl
put abbott favor posit focu faster grow
market brand gener emerg market addit
st jude along smaller tuck-in significantli broaden
abbott cardiac devic product portfolio rais firm abil
compet hospit client seek winnow supplier
still forecast mid-single-digit revenu growth abbott
think potenti firm goos growth key
product line meantim see opportun
abbott enhanc effici fuel earn growth address
situat
larg
manag control abbott exceed expect
close profit gap competit set upsid
valuat
low-hang fruit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
abbott manufactur market medic devic blood glucos
monitor kit nutrit healthcar product diagnost product
equip brand gener drug product includ pacemak
formula nutrit liquid adult vessel closur devic lasik
equip abbott deriv approxim sale outsid unit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
regul
hold steadi fair valu estim per
share continu expect top-lin strength
domest launch freestyl libr on-going adopt
alin system comprehens test panel
stabil infant formula market china
new regulatori hurdl process obtain infant
formula clearanc china somewhat pain
number
competitor expect benefit
abbott maintain optimist expect growth
electrophysiolog neuromodul product
thank new product launch underli
growth demand expect manag abl
meet goal million cost synergi year four
project approxim revenu growth
fuel acquisit aler averag annual
sale growth
still see potenti improv profit abbott
remain busi turn key factor
valuat consolid basi abbott oper
margin significantli trail key competitor
variou busi segment good news abbott
compet sever market offer rel high
margin includ nutrit brand gener drug
cardiovascular devic addit abbott alreadi
begun effort improv product effici
streamlin distribut channel build new facil
lower-cost locat like china india expect
abbott partial close oper margin gap
project basi point improv firm
leverag distribut infrastructur built
penetr emerg market across product
segment extract cost synergi recent
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium
bullish scenario put abbott valu per
share case assum abbott averag
top-lin growth thank addit st jude aler
well outsiz gain pediatr adult nutrit
intern double-digit growth molecular diagnost
greater penetr cardiovascular devic oversea
also assum abbott reach level manufactur
expens compar key competitor like dr
reddi along oper margin
peak
bear case abbott per share
scenario top line averag annual follow
addit st jude aler howev assum
declin stent sale
offer superior technolog long haul mute
perform
low-single-digit growth nutrit low-single-digit
growth diagnost assum abbott rais
gross margin basi point
portico
think addit st jude push abbott toward
wider side narrow moat fulli convinc
abbott tip wide moat categori
especi firm nurtur kind on-going
occasion revolutionari innov necessari
secur reimburs longer term
case abbott one three four competitor
domin market includ nutrit cardiac
monitor coronari stent immunoassay
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
mainli sold outsid busi frequent call
brand gener oper like consum busi
tradit brand drug exampl abbott
brand gener mainli sold less develop
market often lack well-develop infrastructur
distribut instead abbott must sell product directli
pharmaci chain physician result brand
recognit reput key factor abbott
leverag sell fragment market also translat
less price pressur abbott could chang
longer term emerg market turn
tender system character develop nation
howev chang remain
near medium term think abbott benefit
addit st jude impress expertis
cardiac rhythm manag structur heart heart
failur howev juri still abbott abil
nurtur renew innov area long haul
abbott demonstr compet launch
next-gener product lifeblood devic
busi less enthusiast attempt
greater leap innov
final abbott reli intellectu properti ward
competitor devic diagnost segment
think firm earn narrow moat four
segment translat narrow moat entir
potenti price pressur variou sourc
across abbott market exampl trend toward
brand gener declin
reimburs vascular devic firm
invest pipelin lead stream new
product fortifi price power medium
term abbott scale divers help steadi moat
market abbott particip ration oligopoli
enjoy benefit intang asset
think nutrit busi one moatiest
part new abbott wield leadership posit
highli consolid market estim
billion world-wide asid strength develop
market firm face brighter growth prospect
emerg market growth middle-class
famili spur demand pediatr adult nutrit
product thank strong similac ensur brand
abbott advantag posit introduc new
formul line extens penetr new
market abbott made substanti invest earli
build infrastructur emerg market includ
new ventur new zealand-bas build
large-scal dairi farm hub china firm
reap reward invest expand
build block experi nutrit
also play well appli abbott
establish pharmaceut product segment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
trend anticip strength cardiac devic segment
divis diabet busi off-set
current weak intern nutrit molecular
abbott abil deploy robust predict cash
flow
busi toward acquisit
partnership help replenish pipelin
support abbott growth also keep smaller
compani gain critic mass encroach
abbott narrow moat abbott develop
revolutionari devic pipelin candid demonstr
strongli favor clinic outcom acquir
extens collect med-tech product allow
comprehens partner hospit
consid turn moat trend rate posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oabbott xienc stent remain powerhous
well-
drug-elut stent market thank
establish record safeti efficaci
oaggress cost-cut plan propel abbott
bottom-lin growth quickli top-lin growth
oabbott sale establish pharma busi
develop market acquisit
veropharm put abbott brand gener
busi strong posit benefit grow
demand emerg market
oclin data drug-elut stent altern
therapi put crimp percutan coronari
procedur medic therapi coronari bypass
gain favor
oabbott face uphil battl molecular
diagnost arena must go head-to-head
market leader roch along energet
upstart like
oslow growth fall birth rate china offer
abbott nutrit
segment could damp nutrit firm
final overcam regulatori chang china
drag growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
larg acquisit st jude medic aler
abbott enjoy less financi flexibl
medium term issu debt share financ
purchas sale vision-car busi
stake abbott debt/ebitda hover around
end manag indic abbott
plan de-lever near term think
bring debt level closer time end
despit increas interest expens anticip
abbott
coverag
ebitda/interest time coverag
rise ensu year
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium like compani
involv medic technolog abbott vulner
threat revolutionari innov competitor
particularli issu medic devic
diagnost busi despit abbott recent effort
better insul recal like infant formula
recal china risk product qualiti issu
recal remain damag firm brand
relationship medic profession hospit
custom payer tighten purs string abbott could
see greater price pressur furthermor hospit
cardiac therapeut area abbott could find
disadvantag compar key rival
johnson johnson final abbott oper
scrutini food drug administr
well regulatori agenc oversea lead
delay product approv product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund invmt co amer
american fund growth fund amer
capit research manag compani
new york mellon corp
share
fund
share
fund
overal rate abbott stewardship standard
compani made impress purchas
past decad includ purchas
billion brought humira sever
recent acquisit piram st jude
medic remain promis yet fulli match
purchas price remain skeptic acquisit
aler point-of-car diagnost seem
add compel valu abbott technolog
distribut bargain posit proprietari
pharma product spun expect
manag new focu remain busi
result greater effici profit
watch care see abbott abl realiz
potenti acquisit made avoid less
mile white took helm ceo chairman
board follow year tenur abbott date
back provid experi need handl
compani mani oper line find somewhat
worrisom white allow non-abbvie-rel
busi becom flabbi watch white
made progress profit front past
sever year still plenti room
improv abbott catch key
competitor board heavili weight
toward independ former execut
publicli trade firm chicago area particularli
pleas see stark former ceo st jude join
board expect experi lead st jude ramp
innov could posit influenc abbott
said think room improv
compens polici -- move away benchmark
involv adjust earn per share ebit
measur focus return invest capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
abbott see decent result thank nutrit
diagnost freestyl libr oct
abbott report third-quart result held
surpris remain track hit full-year
project top bottom line weve made
materi chang forecast plan rais
fair valu estim modestli reflect cash flow realiz
sinc last updat overal think narrow-moat abbott
execut well new product cycl
meaning innov particular adopt alin
diagnost strength electrophysiolog portfolio
ablat irrig cathet newli approv
freestyl libr sensor last day long-term
concern abbott abil nurtur cultur
innov remain mind
pleas see intern pediatr nutrit
return double-digit organ growth nice
return patienc investor display wait
china work new regulatori framework infant
formula last year one largest
multi-national competitor chines market abbott
resourc compli new govern regul
caus smaller nativ formula produc
leav market
continu success freestyl libr flash also
high point abbott set libr price significantli
lower dexcom medtron guardian cgm
system abbott abl take share
suspect draw type patient away multipl
finger stick day addit weve seen
monitor technolog abbott sensor offer
accuraci earlier sensor expect abbott
maintain pressur user-friendli
price libr rais bar
come recent transcathet cardiovascular
therapeut confer surpris coapt
trial result demonstr efficaci mitraclip
patient sever function mitral regurgit
artifact underli heart failur enlarg left
ventricl prospect expand mitraclip
indic beyond degen mitral regurgit
significantli larger pool fmr patient
attract remain somewhat cautiou sever
reason first favor coapt data inconsist
earlier mitra-fr data fail demonstr
benefit month exampl patient outcom
rehospit mortal differ
trial term patient select practition
experi time frame make difficult compar
result nonetheless conflict trial data suggest well
need build studi consensu reach
second clear durabl coapt result
underli heart failur continu progress even
slower rate would seen without mitraclip
pull mitral valv askew three four year
despit current success still hold
question abbott abil consist innov
especi medic devic on-going cultiv
necessari maintain price power
addit seen competitor
move aggress chang basi
competit technolog innov
price entri weve pay particular attent
abbott cardiac rhythm manag segment sinc
launch mri-compat pacemak implant
cardiovert defibril last fall base
histor cycl new product launch would
expect see abbott outpac market growth captur
anywher point market share first
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
see abbott busi pop year-
over-year growth fourth quarter immedi
follow food drug administr approv
product septemb howev energi
dissip three quarter mute result
follow three quarter
manag sign roughli hospit base onto
risk-bas contract featur antibacteri
tyrx envelop contract cover
cost patient whose devic becom infect
implant tyrx
system surmis proposit take
financi risk costli infect mileston
reach critic mass hospit contract
shield firm full brunt abbott new product
perform intern market jul
although abbott post strong second-quart result
ran slightli ahead expect retain
fair valu estim adjust materi
shift valuat robust top-lin growth intern
market off-set anem sale
hamper time new product launch
bottom line abbott larg met expect
first half see littl chang think
abbott narrow econom moat
particularli pleas see pediatr nutrit
segment return growth intern market --
organ aid foreign exchang
tailwind seen segment weigh
regulatori chang china strong second-quart
growth driven china dust final settl
late think abbott reap reward
larger competitor navig
rigor regul result smaller pool
 launch libr freestyl flash continu glucos
monitor gotten strong start could exceed
project growth year continu
think user-friendli product rel
low price help increas penetr cgm use
type diabet patient pool larg stuck
blood glucos meter decad think abbott
grow presenc type segment make harder
rival make inroad
main area weak cardiac-rel -- vascular
rhythm manag
respect less concern vascular
abbott next-gen coronari stent xienc sierra
recent approv adopt product
revers recent declin come quarter there
noth would lead us believ typic back-and-
forth trade market share come launch
new product wont hold time around
hand think abbott could see competit
pressur mute cardiac rhythm manag segment
time despit recent launch mri-compat
pacemak implant cardiovert defibril
organ second quarter manag
chalk acceler batteri replac
think medtron novel risk-bas contract
tyrx antibacteri envelop pacemak icd like
also factor roughli hospit
contract use system along tyrx
envelop significantli reduc probabl
infect averag cost hospit per
patient align practition concern patient
outcom hospit concern cost
complic offer compel proposit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
hospit perspect expect medtron
continu sign hospit kind risk-
base contract also shield firm brunt
competit new product cycl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
